Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M, Whitfield RJ, Farshid G, Manavis J, Chryssidis S, Mayo BJ, Haycox RC, Ho K, Brown MP, D'Andrea RJ, Evdokiou A, Thomas DM, Desai J, Callen DF, Neilsen PM.

Cancer Res. 2014 Feb 1;74(3):921-31. doi: 10.1158/0008-5472.CAN-13-2424. Epub 2013 Dec 13.

2.

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.

Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.

Lab Invest. 2013 Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep 9.

3.

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.

Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O.

Cancer. 2013 Mar 1;119(5):1013-22. doi: 10.1002/cncr.27837. Epub 2012 Nov 16.

4.

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.

Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, Myklebost O.

BMC Cancer. 2011 May 30;11:211:1-11. doi: 10.1186/1471-2407-11-211.

5.

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.

Oncogene. 2007 May 24;26(24):3473-81. Epub 2006 Dec 4.

PMID:
17146434
6.

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin.

Laroche A, Tran-Cong K, Chaire V, Lagarde P, Hostein I, Coindre JM, Chibon F, Neuville A, Lesluyes T, Lucchesi C, Italiano A.

PLoS One. 2015 Oct 1;10(10):e0137794. doi: 10.1371/journal.pone.0137794. eCollection 2015.

7.

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.

Crane EK, Kwan SY, Izaguirre DI, Tsang YT, Mullany LK, Zu Z, Richards JS, Gershenson DM, Wong KK.

PLoS One. 2015 Aug 6;10(8):e0135101. doi: 10.1371/journal.pone.0135101. eCollection 2015.

8.

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.

9.

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O.

Int J Cancer. 2007 Jul 1;121(1):199-205.

11.

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Palani CD, Beck JF, Sonnemann J.

Invest New Drugs. 2012 Feb;30(1):25-36. doi: 10.1007/s10637-010-9510-7. Epub 2010 Aug 3.

PMID:
20680659
12.

Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.

Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J, Tortosa A.

PLoS One. 2011 Apr 5;6(4):e18588. doi: 10.1371/journal.pone.0018588.

13.

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.

14.

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Gamble LD, Kees UR, Tweddle DA, Lunec J.

Oncogene. 2012 Feb 9;31(6):752-63. doi: 10.1038/onc.2011.270. Epub 2011 Jul 4.

15.

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.

Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ.

Clin Cancer Res. 2007 Jun 1;13(11):3380-7.

16.

Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S.

Cell Death Dis. 2011 Apr 21;2:e148. doi: 10.1038/cddis.2011.33.

17.

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.

Cancer Biol Ther. 2010 Jun 1;9(11):936-44. Epub 2010 Jun 27.

PMID:
20418664
18.

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT.

Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. Epub 2006 Jan 27.

19.

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.

Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H, Abei M, Nakagawa I, Hyodo I.

Cancer Sci. 2011 Mar;102(3):605-13. doi: 10.1111/j.1349-7006.2010.01821.x. Epub 2011 Jan 12.

20.

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH.

Neuro Oncol. 2012 Jul;14(7):859-69. doi: 10.1093/neuonc/nos115. Epub 2012 May 16.

Items per page

Supplemental Content

Write to the Help Desk